IP Library Granted Patent US 12,327,614
Granted Patent B2
US 12,327,614 · App. 16/972,458 · Granted Jun 10, 2025

Multi-domain proteins with increased native state colloidal stability

Inventors: Ralph Adams (Slough, GB); James Heads (Slough, GB); Sebastian Kelm (Slough, GB); Alastair David Griffiths Lawson (Slough, GB)
Assignee: UCB BIOPHARMA SRL
G16B15/20C07K16/00G16B15/00G16B30/00G16B40/00G16C20/50C07K2317/52C07K2317/92C07K2317/94G16B5/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,327,614
App. No.
16/972,458
Granted
Jun 10, 2025
Kind
B2
Abstract

The present invention provides a method for generation of multi-domain proteins, more particular antibodies, with an improved native state colloidal stability. The present disclosure provides a method of producing an IgG1 or IgG4 antibody with an improved colloidal stability comprising, in embodiments: calculating for each domain of said IgG1 or IgG4 antibody the total net charge at a given pH; introducing one or more modifications to the amino acid residues of the constant region of said IgG1 or IgG4 antibody to minimize the charge sign difference between the domains, wherein said one or more modification is, or each are, a substitution of a charged amino acid by a polar (non-charged) amino acid; and producing the modified multi-domain protein with improved colloidal stability at the given pH.

Claims (30)

1. A method of producing an IgG4 antibody with an improved colloidal stability comprising:

calculating for each domain of said IgG4 antibody the total net charge at a given pH;

modifying the DNA sequence encoding the IgG4 antibody to introduce one or more modifications to the amino acid residues of the constant region of said IgG 4 antibody to minimize the charge sign difference between the domains, wherein said one or more modification is, or each are, a substitution of a charged amino acid by a polar, non-charged amino acid, wherein said one or more modifications is, or are, selected from the list consisting of residues at positions R133, E137, D203, R214, E356, R409, E419 of Fc domain; and

producing the IgG4 antibody with improved colloidal stability at the given pH.

2. The method of claim 1 additionally comprising:

calculating the hydrophobicity of the domains of said IgG4 antibody;

modifying the DNA sequence encoding the IgG4 antibody to introduce one or more modifications to the hydrophobic residues to decrease the hydrophobicity of the domains; or

calculating for each domain of said IgG4 antibody of interest the number of unpaired charged amino acid residues.

3. The method of claim 1 , wherein the one or more modifications: minimize the number of charged residues.

4. The method of claim 1 , wherein the total net charge at a given pH is calculated by identifying opposite charged residues in the accessible surface area, and wherein the opposite charged residues located within a distance of less than 8 Å from each other are not taken into the determination of the total charge.

5. The method of claim 4 , wherein said distance is less than 5 Å.

6. The method of claim 5 , wherein the total net charge is the sum of unpaired charged residues.

7. The method of claim 1 , wherein said IgG4 antibody is produced using an expression vector.

8. The method of claim 1 , wherein colloidal stability is measured using a PEG induced precipitation assay.

9. The method of claim 1 , wherein one or more of the domains are not modified.

10. A method of producing an IgG1 or IgG4 antibody with an improved colloidal stability comprising:

calculating for each domain of said IgG1 or IgG4 antibody the total net charge at a given pH;

modifying the DNA sequence encoding the IgG1 or IgG4 antibody to introduce one or more modifications to the amino acid residues of the constant region of said IgG1 or IgG4 antibody to minimize the charge sign difference between the domains, wherein said one or more modification is, or each are, a substitution of a charged amino acid by a polar, non-charged amino acid;

modifying the DNA sequence encoding the IgG1 or IgG4 antibody to substitute one or more amino acids at positions 12, 18, 24, 39, 42, 45, 56 and 67 of the light chain and positions 13, 19, 64, 70, 75 and 83 of the heavy chain according to Kabat numbering by another amino acid to remove a positive charge or introduce a negative charge to minimize the charge sign difference between the domains of said IgG1 or IgG4 antibody; and

producing the IgG1 or IgG4 antibody with an improved colloidal stability at the given pH.

11. The method of claim 10 additionally comprising:

calculating the hydrophobicity of the domains of said IgG4 antibody;

modifying the DNA sequence encoding the IgG1 or IgG4 antibody to introduce one or more modifications to the hydrophobic residues to decrease the hydrophobicity of the domains; or calculating for each domain of said IgG4 antibody of interest the number of unpaired charged amino acid residues.

12. The method of claim 10 , wherein the one or more modifications: minimize the number of charged residues.

13. The method of claim 10 , wherein the total net charge at a given pH is calculated by identifying charged residues in the accessible surface area, and wherein the opposite charged residues located within a distance of less than 8 Å from each other are not taken into the determination of the total charge.

14. The method of claim 13 , wherein said distance is less than 5 Å.

15. The method of claim 14 , wherein the total net charge is the sum of unpaired charged residues.

16. The method of claim 10 , wherein said IgG1 or IgG4 antibody is produced using an expression vector.

17. The method of claim 10 , wherein colloidal stability is measured using a PEG induced precipitation assay.

18. The method of claim 10 , wherein one or more of the domains are not modified.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2021
From: ADAMS, RALPH; HEADS, JAMES; KELM, SEBASTIAN; LAWSON, ALASTAIR DAVID GRIFFITHS
To: UCB BIOPHARMA SPRL
Reel/Frame 054893/0295 →
CHANGE OF NAME Recorded Jan 12, 2021
From: UCB BIOPHARMA SPRL
To: UCB BIOPHARMA SRL
Reel/Frame 054970/0841 →
Priority Claims (1)
GB 1809341 · Jun 7, 2018 · national
Continuity (1)
Related Publication 20210166780A1 · Jun 3, 2021
References Cited (16)
US 20040110226A1 · Lazar · 2004 [cited by examiner]
US 20060271306A1 · Dobson · 2006 [cited by examiner]
US 20110257104A1 · Chennamsetty · 2011 [cited by examiner]
EP 2233500A1 · 2010 [cited by applicant]
WO 2008020827A2 · 2008 [cited by applicant]
WO WO2009155518A1 · 2009 [cited by examiner]
WO 2011122011A2 · 2011 [cited by applicant]
Spassov, Velin Z., Andrej D. Karshikoff, and Rudolf Ladenstein. “The optimization of protein-solvent interactions: Thermostability and the role of hydrophobic and electrostatic interactions.” Protein science 4.8 (1995):… [cited by examiner]
International Search Report issued Nov. 19, 2019, in International Appl. No. PCT/EP2019/064635. [cited by applicant]
Burnsteiner et al., “Structure Based Descriptors for the Estimation of Colloidal Interactions and Protein Aggregation Propensities,” PLOS ONE 8(4):e59797 (2013). [cited by applicant]
Chennamsetty et al., “Design of Therapeutic Proteins with Enhanced Stability,” National Academy of Sciences 106(29):11937-11942 (2009). [cited by applicant]
Kuhn et al., “Improved Solution-State Properties of Monoclonal Antibodies by Targeted Mutations,” Journal of Physical Chemistry Part B 121(48):10818-10827 (2017). [cited by applicant]
Perchiacca et al., “Optimal charged mutations in the complementarity-determining regions that prevent domain antibody aggregation are dependent on the antibody scaffold,” Protein Engineering, Design & Selection 27(2):29… [cited by applicant]
Rouet et al., “Stability engineering of the human antibody repertoire,” FEBS Letters 588(2):269-277 (2013). [cited by applicant]
Tiller et al., “Advances in Antibody Design,” Annual Review of Biomedical Engineering 17(1):191-216 (2015). [cited by applicant]
Yadav et al., “The Influence of Charge Distribution on Self-Association and Viscosity Behavior of Monoclonal Antibody Solutions,” Molecular Pharmaceutics, 9(4):791-802 (2012). [cited by applicant]